论文部分内容阅读
目的 评估EBV血请学筛查NPC的效果、EB病毒阳性人群和阴性人群鼻咽癌发生的危险。方法 免疫酶法检测 30～ 5 9岁 42 0 48人血清EB病毒抗体VCA/IgA、EA/IgA ,抗体滴度均≥ 1/ 5为阳性。所有人群随访至 1999年底。结果 筛查第 1年检出 45例鼻咽癌 ( 45 / 42 0 48,10 7.0 2 / 10 5) ,随后 12年 ,30 5 0例VCA/IgA阳性人群鼻咽癌平均发病率 (每年 14 4 .86 / 10 5)高于3895 3阴性人群 (每年 11.98/ 10 5) ,检出的 15 4例鼻咽癌Ⅰ期 72例。结论 如以往报道 ,EB病毒血清学确实可以检出早期鼻咽癌。在首轮筛查后的 12年中 ,VCA/IgA阳性人群鼻咽癌发病危险是阴性人群的12倍。Ⅰ期鼻咽癌放疗后 5年、10年生存率 ( 81.2 5 % ,6 7.39% )显著高于Ⅱ A、Ⅱ B和Ⅲ期鼻咽癌 ( 6 0 .32 % ,2 6 .6 7% )。
Objective To assess the effect of EBV screening on NPC screening and the risk of nasopharyngeal carcinoma in Epstein-Barr virus positive and negative populations. Methods Serum Epstein - Barr virus (VCA) / IgA (EA) / IgA (EA) / IgA antibodies were detected by enzyme immunoassay in 42 to 48 years old population. The antibody titer was ≥ 1/5. All people were followed up until the end of 1999. Results 45 cases of nasopharyngeal carcinoma (45/42 0 48,10 7.0 2/10 5) were detected in the first year of screening, and the average incidence of nasopharyngeal carcinoma in 30 5 0 VCA / IgA positive people 4.86 / 105) were higher than 38953 negative (11.98 / 105 per year), and 154 cases of stage I nasopharyngeal carcinoma were detected in 72 cases. Conclusions As previously reported, Epstein-Barr virus serology indeed detected early NPC. In the 12 years after the first round of screening, the risk of nasopharyngeal cancer in VCA / IgA positive individuals is 12 times greater than in negative controls. The 5-year survival rate of stage I nasopharyngeal carcinoma after radiotherapy was significantly higher than that of stage II A, stage II B and stage III nasopharyngeal carcinoma (81.2%, 26.39% ).